Pediatric Leukemias: Our Clinical Trials

Through clinical trials, our medical experts evaluate the safety and effectiveness of new therapies and diagnostic tools for leukemia. Clinical trials can also help our doctors compare the effectiveness of different aspects of your child's care, or determine the causes of leukemia.

If your child is eligible to participate in a clinical trial, he or she may have access to new therapies that are not yet available elsewhere. Our clinical research team is highly experienced in selecting children who are most likely to benefit from a particular investigational therapy. They can guide you through the process of choosing the most appropriate clinical trial for your child's needs.

Here you can find a list of many of Memorial Sloan-Kettering's current clinical trials for pediatric leukemia. To learn more about a study, choose from the list below.

Showing 14 trials
Titlesort icon Investigator
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies
[Protocol 06-066]
Barker, Juliet, MBBS
A Phase I Study of Clofarabine Plus Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients with Relapsed or Refractory Acute Leukemia
[Protocol 07-012]
Steinherz, Peter, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055]
O'Reilly, Richard, MD
A Phase I Trial of NECTAR: Nelarabine, Etoposide, and Cyclophosphamide in Children with T-Cell Acute Lymphoblastic Leukemia
[Protocol 11-119]
Trippett, Tanya, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024]
O'Reilly, Richard, MD
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
[Protocol 06-125]
Boulad, Farid, MD
A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib
[Protocol 11-030]
Shukla, Neerav, MD
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
[Protocol 08-008]
Castro-Malaspina, Hugo, MD
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
[Protocol 07-035]
Hsu, Katharine, MD, PhD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069]
Offit, Kenneth, MD
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014]
Barker, Juliet, MBBS
Phase I Study of Actinium-225-Labeled HuM195 Antibody in Patients with Advanced Myeloid Malignancies
[Protocol 02-017]
Jurcic, Joseph, MD
Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia
[Protocol 11-002]
Shukla, Neerav, MD